PROBLEMS OF TESTOSTERONE DEFICIENCY AND ERECTILE DYSFUNCTION IN MEN (LITERATURE REVIEW)


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Ru In recent years, treatment of men with testosterone deficiency has become an important part of andrological and urological practice. Clinical manifestations of testosterone deficiency syndrome are usually diverse. Testosterone deficiency and erectile dysfunction often occur against the background of some systemic diseases, and sometimes are markers or predictors of these diseases. It is important that erectile dysfunction and testosterone deficiency syndrome are closely interrelated, and the correction of these conditions requires account of specific treatment of both diseases.

全文:

受限制的访问

作者简介

Kh. Ibishev

FATPRS SBEI HPE RostSMU of RMPH

Email: ibishev22@mail.ru
Department of Urology and Human Reproductive Health with the course of Pediatric Urology-Andrology FATPRS

I. Khripun

FATPRS SBEI HPE RostSMU of RMPH

Department of Endocrinology with the course of Pediatric Endocrinology

Z. Gusova

FATPRS SBEI HPE RostSMU of RMPH

Department of Endocrinology with the course of Pediatric Endocrinology

I. Belousov

FATPRS SBEI HPE RostSMU of RMPH

Department of Urology and Human Reproductive Health with the course of Pediatric Urology-Andrology FATPRS

A. Cherny

FATPRS SBEI HPE RostSMU of RMPH

Department of Urology and Human Reproductive Health with the course of Pediatric Urology-Andrology FATPRS

E. Dzantieva

FATPRS SBEI HPE RostSMU of RMPH

Department of Endocrinology with the course of Pediatric Endocrinology

M. Kogan

FATPRS SBEI HPE RostSMU of RMPH

Department of Urology and Human Reproductive Health with the course of Pediatric Urology-Andrology FATPRS

参考

  1. Mosli H.A. Practical Aspects of Testosterone Deficiency Syndrome in Clinical Urology. African J. Urol. 2012;18:103-107.
  2. Wang C., Nieschlag E., Swerdloff R.S. et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male. 2009;12:5-12.
  3. Kelly D., Jones T. Testosterone: a metabolic hormone in health and diseas. J. Endocrin. Society for Endocrinology in Great Britain. 2013;217(3):R25-R45.
  4. Saad F., Yassin A.A., Haider A., Gooren L. Effects of testosterone on the lower urinary tract go beyond the prostate: new insights, new treatment options. Arab. J. Urology. 2011; 9:147-152.
  5. Dandona P., Rosenberg M.T. A practical guide to male hypogonadism in the primary care setting.International. J. Cli. Practice. 2010; 64(6):682-696.
  6. Yassin A.A., Saad F., Haider A., Gooren L. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab. J. Urology. 2011; 9:57-62.
  7. Morales A., Bella A.J., Chun Setal. A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can. Urol. Assoc. J. 2010;4(4):269-275.
  8. Greenspan M.B. Erectile dysfunction and testosterone deficiency syndrome: the «portal to men's healt» / // Canad. J. Urology. 2012. Suppl. 1. P. 18-27.
  9. Greenspan M.B., Barkin J. Erectile dysfunction and hypogonadism (low testosterone). Urology. 2011;18(Suppl. 1):2-7.
  10. Tsujimura A. The relationship between testosterone deficiency and men’s health. World J. Mens Health. 2013;31(2):126-135.
  11. Krause W., Mueller U., Mazur A. Testosterone supplementation in the aging male: which questions have been answered? Aging male. 2005;8(1):31-38.
  12. Surampudi P.N., Wang C., Swerdloff R. Hypogonadism in the aging male diagnosis, potential Benefits, and risks of testosterone replacement therapy. Int. J. Endocrinol. 2012; Id 625434. 20 p.
  13. Dhir R.R., Lin H.C., Canfield S.E., Wang R. Combination therapy for erectile dysfunction: an update review. Asian. J. Androl. 2011;13(3): 382-390.
  14. Araujo A.B., Esche G.R., Kupelian V. et al. Prevalence of symptomatic androgen deficiency in men. J. Clin. Endocrinol. Metab. 2007;92:4241.
  15. Wu F.C., Tajar A., Beynon J.M. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 2010;363:123-135.
  16. Rabijewski M., Papierska L., Kozakowski J., Zgliczynski W. The high prevalence of testosterone deficitncy in population of Polish mtn over 65 years with erectile dysfunctions. Aging Male. 2012;4:258-262.
  17. Spets Holm A.C., Fredrikson M.G., Hammar M.L. Symptoms of testosterone deficiency in early middle aged men. Aging Male. 2012;15(2):78-84.
  18. Traish A.M. Adverse health effects of testosterone deficiency (TD) in men. Steroids. 2014;88C:106-116.
  19. Hackett G., Cole N., Bhartia M. et al. Blast Study Group. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int. J. Clin. Pract. 2014;68(2):203-215.
  20. Finkelstrein J.S., Lee H., Burnett-Bowie S.A. et al. Gonodal steroids and body composition, strength, and sexual tunction in men. N. Engl. J. Med. 2013;369:1011-1022.
  21. Shi M.D., Chao J.K., Ma M.C. et al. Factors Associated with Sex Hormones and Erectile Dysfunction in Male Taiwanese Participants with Obesity. J. Sex Med. 2014;11(1):230-239.
  22. Jain P., Radermarker A.W., Mcvary K.T. Testosterone supplementation for erectile dysfunction: results of meta-analysis. J. Urology. 2006;164:371-375.
  23. Isidori A.M., Buvat J., Corona G. et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment-a systematic review. Eur. Urol. 2014; 65(1):99-112.
  24. Zitzmann M., Nieschlag E. Testosterone Substitution: Currrent Modalities and Perspectives. J. Reproduktionsmed. Endokrinol. 2006;3(2):109-116.
  25. Tomada N., Tomada I., Botelho F. et al. Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of Angiopoietin imbalance? Andrology. 2013;1:541-548.
  26. Traish A.M., Galoosian A. Androgens modulate endothelial function and endothelial progenitor cells in erectile physiology. Korean. J. Urol. 2013;54:721-731.
  27. Traish A.M., Abu-Zahra H., Guay A.T. The brain, the penis and steroid hormones: clinical correlates with endothelial dysfuction. Curr. Pharm. Des. 2008;14:3723-3736.
  28. Lu Y.L., Kuang L., Zhu H. et al. Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5 alpha-reductase inhibitor. Asian. J. Androl. 2007;9:843-847.
  29. Kelly D.M., Jones T.H. Testosterone: a vascular hormone in health and disease. J. Endocrinol. 2013;217: R47-71.
  30. Miner M. The Metabolic Investigation of Erectile Dysfunction: Cardiometabolic Risk Stratification. Diabetes Metab. 2014;5:6.
  31. De Berardis G., Franciosi M., Belfiglio M. et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25:284-291.
  32. Zitzman M., Faber S., Nieschlag E., Zitzman M. Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 2006;91:4335-4343.
  33. Ogbera O.A., Sonny C., Olufemi F., Wale A. Hypogonadism and subnormal total testosterone levels in men with type 2 diabetes mellitus. J. Coll. Physicians. Surg. Pak. 2011;21(9):517-521.
  34. Grossmann M., Thomas M.C., Panagiotopoulos S. et al. Low testosterone levels are common and associated with insulin resistance in menwith diabetes.J. Clin. Endocrinol. Metab. 2008; 93: 1834-1840.
  35. Brand J.S., van der Tweel I., Grobbee D.E. et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol. 2011;40:189-207.
  36. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta -analysis. JAMA. 2006;295(11):1288-1299.
  37. Jannini E.A., Isidori A.M., Gravina G.I. et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J. Sex Med. 2009;6(9):2547-2560.
  38. Aversa A., Bruzziches R., Francomano D. et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24 month, randomized, double-blind, placebo-controlled study. J. Sex Med. 2010;7:3495-3503.
  39. Giltay E.J., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. J. Sex Med. 2010;7:2572-2582.
  40. Hackett G., Cole N., Bhartia M. et al. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J. Sex Med. 2013;10:1612-1627.
  41. Wang C., Nieschalag E., Swerdloff R. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendation. J. Androl. 2009;30:1-9.
  42. Ибишев Х.С., Гусова З.Р., Черный А.А., Дзантиева Е.О., Коган М.И. Взаимосвязь дефицита тестостерона и эректильной дисфункции. Поликлиника. 2914;5(1):81-84.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##